Spruce biosciences and kaken pharmaceutical announce strategic partnership and exclusive licensing agreement to develop and commercialize tildacerfont for cah in japan

South san francisco, calif. & tokyo--( business wire )--spruce biosciences, inc. (nasdaq: sprb) and kaken pharmaceutical co. ltd (tokyo stock exchange: 4521) today announced that the companies have entered into an exclusive licensing agreement for the development and commercialization of spruce's product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia (cah) in japan.
SPRB Ratings Summary
SPRB Quant Ranking